Dyslipidemia & Cardiovascular Prevention
Apply prevention principles to reduce cardiovascular morbidity and mortality across primary- and secondary-prevention settings.
Module format: each study session covers what to learn, how the presentation appears clinically, investigation/management priorities, safety issues and common MCCQE traps.
Module 11 — Topic map
- Cardiovascular risk assessment and major modifiable/non-modifiable risk factors
- Lifestyle counselling: smoking cessation, physical activity, dietary pattern, weight and alcohol/substance considerations
- Lipid profile interpretation and common causes of secondary dyslipidemia
- Statin therapy principles in primary and secondary prevention
- Management when LDL remains elevated despite initial therapy
- Familial hypercholesterolemia clues and family screening concepts
- Cardiovascular prevention in diabetes, CKD and established atherosclerotic disease
- Medication adherence, shared decision-making and communicating absolute benefit/risk
Health PromotionChronic CareCommunicationRisk reduction
Study Session 11.1 — Cardiovascular Risk Assessment & Lifestyle Prevention
Focused MCCQE cardiovascular study session
Core topics & learning goals
- Identify age, smoking, BP, diabetes, lipids, CKD and family history as major risk inputs.
- Communicate absolute versus relative benefit.
- Counsel on smoking cessation, physical activity, dietary pattern and weight.
- Use motivational interviewing/shared decision-making principles.
Clinical recognition & investigation
- Screen for barriers including cost, literacy, mental health and social determinants.
- Prioritize the highest-impact modifiable risks.
Management & patient-safety priorities
- Set measurable goals and follow up adherence.
- Use pharmacotherapy when indicated in addition to lifestyle measures.
MCCQE exam traps
- Do not present lifestyle and medication as mutually exclusive when both are indicated.
- Avoid stigmatizing weight-focused communication.
Study Session 11.2 — Dyslipidemia & Statin-Based Prevention
Focused MCCQE cardiovascular study session
Core topics & learning goals
- Interpret lipid profile and identify secondary causes.
- Understand primary versus secondary prevention and intensity concepts.
- Recognize familial hypercholesterolemia clues.
- Know common statin adverse effects/interactions and how to evaluate symptoms.
Clinical recognition & investigation
- Assess baseline ASCVD risk, diabetes, CKD and established vascular disease.
- Use follow-up lipids/adherence assessment appropriately.
Management & patient-safety priorities
- Start/intensify statin-based therapy when indicated and add non-statin therapy for selected high-risk patients.
- Address adherence and secondary causes before assuming treatment failure.
MCCQE exam traps
- A mildly elevated liver enzyme value does not automatically contraindicate statin therapy; assess context.
- Do not use LDL alone without the patient’s overall risk context.
Study Session 11.3 — Secondary Prevention After ASCVD
Focused MCCQE cardiovascular study session
Core topics & learning goals
- Integrate antiplatelet therapy, lipid lowering, BP/diabetes control, smoking cessation and cardiac rehabilitation.
- Review post-MI medication classes and duration concepts.
- Recognize medication interactions and bleeding risks.
- Address return to activity/work and adherence.
Clinical recognition & investigation
- Look for recurrent angina, HF, arrhythmia, depression and functional limitation.
- Review vaccination and comorbidity management where appropriate.
Management & patient-safety priorities
- Create a longitudinal prevention plan and coordinate primary/specialty care.
- Use communication to improve adherence and shared decisions.
MCCQE exam traps
- Secondary prevention continues after symptoms resolve.
- Do not stop antiplatelet therapy around procedures without assessing stent/ischemic risk and coordinating care.